License-out交易

Search documents
翰森制药2025H1业绩:创新国际化驱动 总收入74.34亿元,溢利同比增长15.0%达31.35亿元
Zhong Guo Jin Rong Xin Xi Wang· 2025-08-20 13:44
Core Viewpoint - Hansoh Pharmaceutical reported a strong performance in the first half of 2025, with significant revenue growth driven by innovative drugs and collaboration products. Financial Performance - Revenue for the first half of 2025 was approximately RMB 74.34 billion, a year-on-year increase of about 14.3% [1] - Profit for the same period was approximately RMB 31.35 billion, reflecting a year-on-year growth of about 15.0% [1] - Basic earnings per share were approximately RMB 0.53, up by about 14.8% year-on-year [1] - The interim dividend declared was HKD 0.2316 per share [1] Product Sales - Sales revenue from innovative drugs and collaboration products reached RMB 61.45 billion, a year-on-year increase of 22.1%, accounting for 82.7% of total revenue [1] - The anti-tumor product Aumseqa® generated approximately RMB 45.31 billion in revenue, representing about 60.9% of total revenue [2] - Aumseqa® received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in June 2025, marking it as the first overseas launch of a Chinese original EGFR-TKI [2] Research and Development - R&D expenditure for the first half of 2025 was approximately RMB 14.41 billion, a year-on-year increase of 20.4%, constituting about 19.4% of total revenue [1] - The company is advancing over 70 innovative drug clinical trials across more than 40 candidate drugs [1] - Notable candidates entering Phase III clinical trials include B7-H3 targeted ADC (HS-20093) and B7-H4 targeted ADC (HS-20089) [1] Collaborations and Licensing - In December 2024, the company entered a global exclusive licensing agreement with MSD for the oral small molecule GLP-1 receptor agonist HS-10535, receiving an upfront payment of USD 112 million [2] - In June 2025, the company granted Regeneron exclusive overseas licensing for the dual GLP-1/GIP receptor agonist HS-20094, receiving an upfront payment of USD 80 million and potential milestone payments of up to USD 1.93 billion [2] Financial Stability - The net cash inflow from operating activities for the first half of 2025 was RMB 36.05 billion [3] - The company had cash and bank deposits totaling RMB 271.04 billion, indicating a robust financial position to support ongoing innovation and R&D investments [3]